https://www.nasdaq.com/press-release/allogene-therapeutics-to-present-at-the-virtual-40th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/allogene-therapeutics-expands-headquarters-to-support-company-growth-and-pipeline
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-positive-results-from-phase-1-universal-study-of-single
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-positive-phase-1-data-from-the-alpha-trials-in-non
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-conference-call-to-review-alpha-alpha2-and-universal
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-five-upcoming-virtual-investor-0
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-third-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/allogene-therapeutics-to-showcase-clinical-data-from-the-alpha-alpha2-and-universal
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-third-quarter-financial-results-on-november-4-2021
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-fda-clinical-hold-of-allocar-t-trials-based-on-a-single
https://www.nasdaq.com/press-release/allogene-therapeutics-adds-renowned-car-t-expert-jae-park-m.d.-to-its-scientific
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor-1
https://www.nasdaq.com/press-release/allogene-therapeutics-receives-fda-orphan-drug-designation-odd-for-allo-715-for-the
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-second-quarter-2021-financial-results-2021-08-04
https://www.nasdaq.com/press-release/allogene-therapeutics-appoints-industry-leaders-elizabeth-liz-barrett-and-vicki-sato
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-second-quarter-financial-results-on-august-4-2021
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor-0
https://www.nasdaq.com/press-release/allogene-therapeutics-granted-fda-fast-track-designation-for-allo-605-the-first
https://www.nasdaq.com/press-release/allogene-overland-biopharm-appoints-shuyuan-yao-as-chief-executive-officer-2021-06-21
https://www.nasdaq.com/press-release/allogene-therapeutics-presents-positive-phase-1-data-on-allo-501-and-allo-501a-in
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-five-upcoming-virtual-investor
https://www.nasdaq.com/press-release/allogene-therapeutics-cd19-forum-highlights-positive-results-from-phase-1-studies-of
https://www.nasdaq.com/press-release/allogene-therapeutics-to-host-virtual-cd19-forum-on-may-19-2021-2021-05-13
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-first-quarter-2021-financial-results-2021-05-05
https://www.nasdaq.com/press-release/allogene-therapeutics-to-present-data-from-its-anti-cd19-allocar-ttm-therapy-program
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-first-quarter-financial-results-on-may-5-2021-2021-04
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-rmat
https://www.nasdaq.com/press-release/allogene-therapeutics-receives-ind-clearance-from-the-u.s.-food-and-drug-0
https://www.nasdaq.com/press-release/allogene-therapeutics-and-springworks-therapeutics-announce-dosing-of-first-patient
https://www.nasdaq.com/press-release/allogene-therapeutics-presents-preclinical-research-highlighting-a-novel-turbocartm-t
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/notch-therapeutics-closes-%2485-million-series-a-financing-to-develop-pipeline-of
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-four-upcoming-virtual-investor
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-ton-schumacher-ph.d.-chair-of-scientific-advisory-0
https://www.nasdaq.com/press-release/allogene-therapeutics-to-present-at-the-virtual-39th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/allogene-therapeutics-receives-ind-clearance-from-the-u.s.-food-and-drug
https://www.nasdaq.com/press-release/allogene-therapeutics-and-overland-pharmaceuticals-form-joint-venture-in-greater
https://www.nasdaq.com/press-release/allogene-therapeutics-presents-preclinical-findings-supporting-allo-605-the-first
https://www.nasdaq.com/press-release/allogene-therapeutics-presents-preclinical-data-on-allo-316-in-acute-myeloid-leukemia
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-positive-initial-results-from-phase-1-universal-study
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-webinar-to-review-initial-allo-715-phase-1-data-on
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-november-and-december-2020-virtual-investor
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-oral-presentation-of-initial-results-from-its-phase-1
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-third-quarter-2020-financial-results-2020-11-04
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-third-quarter-2020-financial-results-on-november-4
https://www.nasdaq.com/press-release/allogene-therapeutics-and-md-anderson-announce-strategic-collaboration-to-accelerate
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-october-2020-virtual-investor-conference
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-september-2020-virtual-investor-conference
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-second-quarter-2020-financial-results-2020-08-05
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-second-quarter-2020-financial-results-on-august-5
https://www.nasdaq.com/press-release/notch-therapeutics-appoints-david-main-as-president-and-chief-executive-officer-to
https://www.nasdaq.com/press-release/allogene-therapeutics-adds-immunotherapy-luminaries-thomas-f.-gajewski-m.d.-ph.d.-and
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-ton-schumacher-ph.d.-chair-of-scientific-advisory
https://www.nasdaq.com/press-release/allogene-therapeutics-presents-preclinical-findings-supporting-an-allogeneic-dll3-car
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-publication-highlighting-potential-for-allo-819-in
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-june-2020-virtual-investor-conference-participation
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-pricing-of-public-offering-of-common-stock-2020-06-01
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-commencement-of-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/allogene-therapeutics-with-collaborator-servier-reports-positive-results-from-its
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-webinar-to-review-initial-allo-501-phase-1-data-on
https://www.nasdaq.com/press-release/american-society-of-clinical-oncology-asco-abstract-reports-initial-allo-501-alpha
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-first-quarter-2020-financial-results-2020-05-06
https://www.nasdaq.com/press-release/allogene-therapeutics-in-collaboration-with-servier-to-present-initial-results-from
https://www.nasdaq.com/press-release/allogene-therapeutics-to-present-preclinical-findings-supporting-turbocartm
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-first-quarter-2020-financial-results-on-may-6-2020
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-participation-in-two-upcoming-virtual-investor
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-february-and-march-2020-investor-conference-schedule
https://www.nasdaq.com/press-release/allogene-therapeutics-and-springworks-therapeutics-announce-clinical-collaboration-to
https://www.nasdaq.com/press-release/allogene-therapeutics-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-year-end-2019-media-event-and-investor-conference
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-pre-clinical-data-presentations-supporting-allocar
https://www.nasdaq.com/press-release/allogene-therapeutics-reports-third-quarter-2019-financial-results-2019-11-05
https://www.nasdaq.com/press-release/allogene-therapeutics-and-notch-therapeutics-announce-collaboration-to-research-and
https://www.nasdaq.com/press-release/allogene-therapeutics-to-report-third-quarter-2019-financial-results-on-november-5
https://www.nasdaq.com/press-release/allogene-therapeutics-enters-research-collaboration-directed-at-enhancing-future
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-publication-preclinical-study-results-molecular
https://www.nasdaq.com/press-release/allogene-therapeutics-announces-april-2019-investor-conference-schedule-2019-04-21
